Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.2 CHF -1.1% Market Closed
Market Cap: 140.1m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

Relative Value

The Relative Value of one NWRN stock under the Base Case scenario is 3.45 CHF. Compared to the current market price of 7.2 CHF, Newron Pharmaceuticals SpA is Overvalued by 52%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NWRN Relative Value
Base Case
3.45 CHF
Overvaluation 52%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
12
vs Industry
11
Median 3Y
10.5
Median 5Y
9.1
Industry
2.5
Forward
6.5
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-2.3
Industry
21.9
Forward
71.8
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-3.1
Industry
16.5
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-5.1
Industry
23.6
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
0.9
Industry
2.1
vs History
7
vs Industry
9
Median 3Y
12.9
Median 5Y
8.4
Industry
2.6
Forward
8.1
vs History
9
vs Industry
10
Median 3Y
13.9
Median 5Y
9
Industry
5.2
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-3.8
Industry
13.3
Forward
32.4
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-3.7
Industry
16.6
Forward
33.8
vs History
vs Industry
Median 3Y
-9.6
Median 5Y
-3.9
Industry
15.6
vs History
vs Industry
Median 3Y
-9.6
Median 5Y
-3.9
Industry
19.1
vs History
7
vs Industry
8
Median 3Y
8.5
Median 5Y
3.4
Industry
1.9

Multiples Across Competitors

NWRN Competitors Multiples
Newron Pharmaceuticals SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Newron Pharmaceuticals SpA
SIX:NWRN
137.1m CHF 21.1 -7.8 -12.4 -12.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average P/E: 32.4
Negative Multiple: -7.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top